FDA Approves Sanofi’s and Regneron’s Dupixent to Treat Eosinophilic Esophagitis

Dupixent (dupilumab), developed by Regeneron Pharmaceuticals in partnership with Sanofi, has received FDA approval for a new indication—treating eosinophilic esophagitis, a chronic inflammatory disease.